Abstract: The Bacillus subtilis ZF-1 and use thereof in inhibiting African swine fever virus are provided. A Bacillus subtilis strain (CCTCC NO: M2022185) is screened and selected from 95 self-preserved strains with an inhibiting effect on African swine fever virus. The strain has a remarkable anti-ASFV effect in vivo and in vitro through anti-infection research at a cell level and an animal body level, can reduce proliferation of the virus in a pig body and damage of ASFV infection to tissues and organs, can effectively control adverse effects of ASFV infection on the body, and can be used for preventing and controlling African swine fever epidemics.

Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test.